Twitter

Posts Tagged ‘recruiting’


Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients After 8-week Routine Therapy Evaluated as SD

Condition :   NSCLC Interventions :   Drug: Icotinib of routine dose;   Drug: Icotinib of high dose Sponsors :   Zhejiang Beta Pharma Inc.;   Zhejiang Beta Pharma Inc. Recruiting – verified September 2012

Read More...

A Study of Vemurafenib Alone And Vemurafenib in Combination With GDC-0973 in Patients With Malignant Melanoma

Condition :   Malignant Melanoma Interventions :   Drug: vemurafenib;   Drug: Placebo;   Drug: GDC-0973 Sponsors :   Hoffmann-La Roche;   Hoffmann-La Roche Not yet recruiting – verified September 2012

Read More...

Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma

Condition :   Metastatic Melanoma Interventions :   Drug: Ipilimumab;   Other: Radiation Therapy and Ipilimumab Sponsors :   New York University School of Medicine;   New York University School of Medicine Not yet recruiting – verified September 2012

Read More...

Triciribine and Carboplatin in Ovarian Cancer

Condition :   Ovarian Cancer Interventions :   Drug: Triciribine;   Drug: Carboplatin Sponsors :   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Department of Defense;   Cahaba Pharmaceuticals Not yet recruiting – verified September 2012

Read More...

Comparison of Surgical Approach to Endoscopic Pituitary Adenoma Resection

Conditions :   Pituitary Adenoma;   Posterior Septectomy;   Stamm Approach;   Quality of Life Interventions :   Procedure: Stamm Approach;   Procedure: Posterior Septectomy Sponsors :   University of Calgary;   University of Calgary Recruiting – verified September 2012

Read More...

Pomalidomide for Chronic Graft-versus-Host Disease

Conditions :   Graft vs Host Disease;   Graft-Versus-Host Disease Intervention :   Drug: Pomalidomide Sponsors :   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI) Recruiting – verified August 2012

Read More...

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery

Conditions :   Childhood Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma Interventions :   Drug: tivantinib;   Drug: erlotinib hydrochloride Sponsors :   National Cancer Institute (NCI);   National Cancer Institute (NCI) Recruiting – verified September 2012

Read More...

A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma

Conditions :   Micropapillary Cancer of the Bladder;   Squamous Cell Carcinoma of the Bladder;   Bladder Cancer With Bone Metastases;   Bladder Cancer;   Small Cell Cancer of the Bladder;   Urachal Cancer;   Sarcomatoid Bladder Cancer Interventions :   Drug: Cabozantinib;   Procedure: FDG PET CT;   Procedure: NaF PET CT Sponsors :   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI) Recruiting – verified September 2012

Read More...

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Condition :   Prostate Cancer Intervention :   Drug: Ipilimumab Sponsors :   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Bristol-Myers Squibb;   Duke University;   Northwestern University;   Oregon Health and Science University Recruiting – verified September 2012

Read More...

Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma

Condition :   Esophageal Squamous Cell Carcinoma Resectable Intervention :   Drug: Nimotuzumab combined with paclitaxel and cisplatin Sponsors :   Zhejiang Cancer Hospital;   Zhejiang Cancer Hospital Recruiting – verified September 2012

Read More...